Noveris Health Sciences Announces Debenture Conversion

Vancouver, British Columbia — March 6, 2026 — Leads & Copy — Noveris Health Sciences Inc. (CSE: NVRS) has announced the conversion of debentures totaling $8,188,628, resulting in the issuance of 47,687,939 common shares. The conversion was initiated at the option of the debenture holders, with the debentures originally issued on October 14, 2025.

The debentures converted at a price of $0.192682432 per share, based on the 20-day trailing volume-weighted average trading price of the company’s common shares as of the conversion date.

JJK Holdings Ltd. (JJK) had previously acquired a debenture with a principal amount of $7,878,792 from Pioneer Garage Limited. This debenture was fully converted into 40,890,039 common shares and then transferred to 23 parties, all at arm’s length to JJK, except for a wholly owned subsidiary of JJK. Following the conversion, none of the transferees hold 10% or more of the company’s outstanding shares.

Joshua Bartch, the chief executive officer and a director of Noveris Health Sciences, also converted his debenture with a principal amount of $1,309,836, resulting in the issuance of 6,797,900 common shares to him.

Prior to the debenture conversion, the company had 1,235,061 common shares issued and outstanding.

JJK, through its subsidiary, now holds 3,848,706 common shares, representing 7.86% of the company’s issued and outstanding shares. Mr. Bartch now holds 6,827,419 common shares, representing 13.95% of the company’s issued and outstanding shares.

JJK acquired the common shares for investment purposes and may acquire additional securities or adjust its holdings depending on market conditions and other factors.

Mr. Bartch also acquired the common shares for investment purposes and may increase or decrease his holdings based on market and economic conditions.

This announcement is issued in compliance with National Instrument 62-103 and National Instrument 62‑104, pertaining to early warning systems and take-over bids. Copies of the Early Warning Reports will be available on the SEDAR+ website.

Noveris Health Sciences Inc. is a biotechnology company focused on developing innovative medications and therapies for mental health disorders, including nicotine addiction and PTSD. The company combines advanced technology with infrastructure for drug discovery and development, collaborating with specialists to accelerate the development of safer and more effective treatments. Noveris is also focused on creating innovative compounds with therapeutic potential through clinical trials.

Source: Noveris Health Sciences Inc.